Optimal care for familial hypercholesterolaemia (FH) requires patient-centred management,
multidisciplinary teamwork, involvement of primary care practitioners, patient networks …

Adverse drug reactions (ADRs) rank as one of the top 10 leading causes of death and
illness in developed countries. ADRs show differential features depending upon genotype …

Abstract Purpose of Review Statins are first-line therapy for lowering low-density lipoprotein
(LDL) cholesterol in familial hypercholesterolemia (FH), particularly in heterozygous …

Abstract Background Heterozygous familial hypercholesterolemia (HeFH) is largely
underdiagnosed and undertreated in China where few patients achieved recommended …

In this study, we establish a population-based human induced pluripotent stem cell (hiPSC)
drug screening platform for toxicity assessment. After recruiting 1,000 healthy donors and …

Abstract Purpose The 3-hydroxy-3-methylglutaryl–coenzyme A reductase inhibitors
(“statins”) and the cholesterol-lowering medication ezetimibe are widely used in the …

Introduction: Statins are the first line of therapy to reduce low-density lipoprotein cholesterol
(LDL-C) in order to decrease cardiovascular events. Pitavastatin is the latest statin to be …

Objective: This study explored the multicomponent, multitarget, and multipathway
mechanism of Danhe granules (DG) against hyperlipidemia through network pharmacology …

Aim The aim of this study was to evaluate the efficacy and safety of evolocumab with
background atorvastatin in Chinese patients with type 2 diabetes mellitus (T2DM) and …

Background Rosuvastatin is a lipid-lowering drug that works by inhibiting 3-hydroxy-3-
methylglutaryl coenzyme A reductase, the rate-limiting enzyme responsible for producing …